Latest Advances in Lung Cancer Research

Study shows nearly half of high-risk lung cancer screenings have delayed follow-up, with current smokers at higher risk of delays in care.

Global lung cancer rates have risen over 30 years with significant regional variations; researchers urge tailored interventions to address this persisting major health issue.

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.

Study finds White Americans 50% more likely to receive lung cancer screenings than Black Americans; health perception influences screening likelihood.

Merck’s Keytruda reduces early-stage lung cancer recurrence by 24% post-surgery, with plans for FDA approval submission, and shows a favorable safety profile.

Canadian researchers developed IPRO, a deep learning model for lung cancer care, enhancing prognosis by analyzing pre-treatment CT scans without manual input.

The FDA rapidly approved Bristol Myers Squibb’s Opdivo for early-stage NSCLC, marking a major advancement in pre-surgical cancer treatment.

FDA skepticism challenges sintilimab’s approval for NSCLC, citing concerns over trial data exclusivity from China and its less favored endpoint of PFS.

The FDA has granted nivolumab (Opdivo) priority review as a neoadjuvant treatment for resectable NSCLC, based on promising CheckMate -816 trial results.

Lung cancer screening disparities persist for Black Americans, with USPSTF guidelines and risk models failing to adequately address racial differences in risk and diagnosis.

Moffitt Cancer Center seeks federal funding for a mobile unit to improve lung cancer screening rates, especially for marginalized communities, aiming for operational status by early 2024.